Canonical NF-κB activation is essential for Epstein-Barr virus latent membrane protein 1 TES2/CTAR2 gene regulation

Journal of Virology

Volumn 85, Issue 13, 2011, Pages 6764-6773

  Gewurz, Benjamin E ^a   Mar, Jessica C ^b,c   Padi, Megha ^b,c   Zhao, Bo ^a   Shinners, Nicholas P ^a   Takasaki, Kaoru ^a   Bedoya, Edward ^b   Zou, James Y ^a   Cahir Mcfarland, Ellen ^a   Quackenbush, John ^b,c   Kieff, Elliott ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

A20 PROTEIN; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LATENT MEMBRANE PROTEIN 1; MESSENGER RNA; REGULATOR PROTEIN; RNA; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; EBV ASSOCIATED MEMBRANE ANTIGEN, EPSTEIN BARR VIRUS; EBV-ASSOCIATED MEMBRANE ANTIGEN, EPSTEIN-BARR VIRUS; MATRIX PROTEIN; PROTEIN;

ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; DOWN REGULATION; EMBRYO; EPSTEIN BARR VIRUS; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE TARGETING; GENETIC CODE; HUMAN; HUMAN CELL; LMP1 TES2 GENE; NEGATIVE FEEDBACK; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; SIGNAL TRANSDUCTION; T LYMPHOCYTE; UPREGULATION; VIRUS GENE; CELL STRAIN HEK293; CHEMISTRY; GENETICS; METABOLISM;

HUMAN HERPESVIRUS 4; RODENTIA;

GENE EXPRESSION REGULATION; HEK293 CELLS; HERPESVIRUS 4, HUMAN; HUMANS; NF-KAPPA B; PROTEINS; RNA; SIGNAL TRANSDUCTION; UP-REGULATION; VIRAL MATRIX PROTEINS;

EID: 80052073170     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00422-11     Document Type: Article

References (69)

1. Baichwal, V. R., and B. Sugden. 1988. Transformation of Balb 3T3 cells by the BNLF-1 gene of Epstein-Barr virus. Oncogene 2:461-467.
2. Beider, K., et al. 2009. Interaction between CXCR4 and CCL20 pathways regulates tumor growth. PLoS One 4:e5125.
3. Ben-Baruch, A. 2006. The multifaceted roles of chemokines in malignancy. Cancer Metastasis Rev. 25:357-371.
4. Benjamini, Y., and Y. Hochberg. 1995. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. Series B 57:289-300.
5. Ben Nasr, H., et al. 2007. Association of IL-8 (-251)T/A polymorphism with susceptibility to and aggressiveness of nasopharyngeal carcinoma. Hum. Immunol. 68:761-769.
6. Berriz, G. F., O. D. King, B. Bryant, C. Sander, and F. P. Roth. 2003. Characterizing gene sets with FuncAssociate. Bioinformatics 19:2502-2504.
7. Boehm, D., B. E. Gewurz, E. Kieff, and E. Cahir-McFarland. 2010. Epstein-Barr latent membrane protein 1 transformation site 2 activates NF-κB in the absence of NF-κB essential modifier residues 133-224 or 373-419. Proc. Natl. Acad. Sci. U. S. A. 107:18103-18108.
8. Brazma, A., et al. 2001. Minimum information about a microarray experiment (MIAME)-toward standards for microarray data. Nat. Genet. 29:365- 371.
9. Breitkreutz, B. J., et al. 2008. The BioGRID Interaction Database: 2008 update. Nucleic Acids Res. 36:D637-D640.
10. Cahir-McFarland, E. D., et al. 2004. Role of NF-kappa B in cell survival and transcription of latent membrane protein 1-expressing or Epstein-Barr virus latency III-infected cells. J. Virol. 78:4108-4119.
11. Cahir-McFarland, E. D., D. M. Davidson, S. L. Schauer, J. Duong, and E. Kieff. 2000. NF-kappa B inhibition causes spontaneous apoptosis in Epstein-Barr virus-transformed lymphoblastoid cells. Proc. Natl. Acad. Sci. U. S. A. 97:6055-6060.
12. Chen, L. F., et al. 2005. NF-κB RelA phosphorylation regulates RelA acetylation. Mol. Cell. Biol. 25:7966-7975.
13. Devergne, O., et al. 1998. Role of the TRAF binding site and NF-κB activation in Epstein-Barr virus latent membrane protein 1-induced cell gene expression. J. Virol. 72:7900-7908.
14. Eisen, M. B., P. T. Spellman, P. O. Brown, and D. Botstein. 1998. Cluster analysis and display of genome-wide expression patterns. Proc. Natl. Acad. Sci. U. S. A. 95:14863-14868.
15. Eliopoulos, A. G., et al. 1997. Epstein-Barr virus-encoded LMP1 and CD40 mediate IL-6 production in epithelial cells via an NF-κB pathway involving TNF receptor-associated factors. Oncogene 14:2899-2916.
16. Eliopoulos, A. G., and L. S. Young. 1998. Activation of the cJun N-terminal kinase (JNK) pathway by the Epstein-Barr virus-encoded latent membrane protein 1 (LMP1). Oncogene 16:1731-1742.
17. Felaco, P., et al. 2009. IL-32: a newly-discovered proinflammatory cytokine. J. Biol. Regul. Homeost. Agents 23:141-147.
18. Ghisletti, S., et al. 2010. Identification and characterization of enhancers controlling the inflammatory gene expression program in macrophages. Immunity 32:317-328.
19. Gires, O., et al. 1997. Latent membrane protein 1 of Epstein-Barr virus mimics a constitutively active receptor molecule. EMBO J. 16:6131-6140.
20. Grivennikov, S. I., F. R. Greten, and M. Karin. 2010. Immunity, inflammation, and cancer. Cell 140:883-899.
21. Haimerl, F., A. Erhardt, G. Sass, and G. Tiegs. 2009. Down-regulation of the de-ubiquitinating enzyme ubiquitin-specific protease 2 contributes to tumor necrosis factor-alpha-induced hepatocyte survival. J. Biol. Chem. 284:495- 504.
22. Hao, S., and D. Baltimore. 2009. The stability of mRNA influences the temporal order of the induction of genes encoding inflammatory molecules. Nat. Immunol. 10:281-288.
23. Hayden, M. S., and S. Ghosh. 2008. Shared principles in NF-κB signaling. Cell 132:344-362.
24. Hori, S. 2010. c-Rel: a pioneer in directing regulatory T-cell lineage commitment? Eur. J. Immunol. 40:664-667.
25. Irizarry, R. A., et al. 2003. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res. 31:e15.
26. Irizarry, R. A., et al. 2005. Multiple-laboratory comparison of microarray platforms. Nat. Methods 2:345-350.
27. Izumi, K. M., et al. 1999. The Epstein-Barr virus oncoprotein latent membrane protein 1 engages the tumor necrosis factor receptor-associated proteins TRADD and receptor-interacting protein (RIP) but does not induce apoptosis or require RIP for NF-κB activation. Mol. Cell. Biol. 19:5759- 5767.
28. Izumi, K. M., K. M. Kaye, and E. D. Kieff. 1997. The Epstein-Barr virus LMP1 amino acid sequence that engages tumor necrosis factor receptor associated factors is critical for primary B lymphocyte growth transformation. Proc. Natl. Acad. Sci. U. S. A. 94:1447-1452.
29. Kanehisa, M., and S. Goto. 2000. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28:27-30.
30. Karin, M. 2009. NF-κB as a critical link between inflammation and cancer. Cold Spring Harb. Perspect. Biol. 1:a000141.
31. Kasowski, M., et al. 2010. Variation in transcription factor binding among humans. Science 328:232-235.
32. Kaye, K. M., K. M. Izumi, and E. Kieff. 1993. Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. Proc. Natl. Acad. Sci. U. S. A. 90:9150-9154.
33. Kaye, K. M., et al. 1999. An Epstein-Barr virus that expresses only the first 231 LMP1 amino acids efficiently initiates primary B-lymphocyte growth transformation. J. Virol. 73:10525-10530.
34. Kaye, K. M., K. M. Izumi, G. Mosialos, and E. Kieff. 1995. The Epstein-Barr virus LMP1 cytoplasmic carboxy terminus is essential for B-lymphocyte transformation; fibroblast cocultivation complements a critical function within the terminal 155 residues. J. Virol. 69:675-683.
35. Kaykas, A., K. Worringer, and B. Sugden. 2001. CD40 and LMP-1 both signal from lipid rafts but LMP-1 assembles a distinct, more efficient signaling complex. EMBO J. 20:2641-2654.
36. Li, J., et al. 2007. Expression of immune-related molecules in primary EBVpositive Chinese nasopharyngeal carcinoma: associated with latent membrane protein 1 (LMP1) expression. Cancer Biol. Ther. 6:1997-2004.
37. Li, M., J. Wang, and J. Chen. 2008. A fast agglomerate algorithm for mining functional modules in protein interaction networks, p. 3-7. Abstr. 2008 Int. Conf. BioMed. Eng. Inform. IEEE Computer Society, Washington, DC.
38. Li, S., L. Wang, M. A. Berman, Y. Zhang, and M. E. Dorf. 2006. RNAi screen in mouse astrocytes identifies phosphatases that regulate NF-κB signaling. Mol. Cell 24:497-509.
39. Liang, J., et al. 2008. A novel CCCH-zinc finger protein family regulates proinflammatory activation of macrophages. J. Biol. Chem. 283:6337-6346.
40. Liebowitz, D., D. Wang, and E. Kieff. 1986. Orientation and patching of the latent infection membrane protein encoded by Epstein-Barr virus. J. Virol. 58:233-237.
41. Luftig, M., et al. 2003. Epstein-Barr virus latent membrane protein 1 activation of NF-κB through IRAK1 and TRAF6. Proc. Natl. Acad. Sci. U. S. A. 100:15595-15600.
42. Luftig, M., et al. 2004. Epstein-Barr virus latent infection membrane protein 1 TRAF-binding site induces NIK/IKK alpha-dependent noncanonical NF-κB activation. Proc. Natl. Acad. Sci. U. S. A. 101:141-146.
43. Matsushita, K., et al. 2009. Zc3h12a is an RNase essential for controlling immune responses by regulating mRNA decay. Nature 458:1185-1190.
44. Moorthy, R. K., and D. A. Thorley-Lawson. 1993. All three domains of the Epstein-Barr virus-encoded latent membrane protein LMP-1 are required for transformation of rat-1 fibroblasts. J. Virol. 67:1638-1646.
45. Morris, M. A., et al. 2008. Epstein-Barr virus-encoded LMP1 induces a hyperproliferative and inflammatory gene expression programme in cultured keratinocytes. J. Gen. Virol. 89:2806-2820.
46. Natoli, G. 2009. Control of NF-κB-dependent transcriptional responses by chromatin organization. Cold Spring Harb. Perspect. Biol. 1:a000224.
47. Naugler, W. E., and M. Karin. 2008. The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol. Med. 14: 109-119.
48. Raab-Traub, N. 2002. Epstein-Barr virus in the pathogenesis of NPC. Semin. Cancer Biol. 12:431-441.
49. Rickinson, A. B., and E. Kieff. 2001. Epstein Barr virus and its replication, p. 2511-2574. In D. M. Knipe and P. M. Howley (ed.), Fields virology, vol. 2. Lippincott Williams & Wilkins, Philadelphia, PA.
50. Schneider, F., et al. 2008. The viral oncoprotein LMP1 exploits TRADD for signaling by masking its apoptotic activity. PLoS Biol. 6:e8.
51. Schultheiss, U., et al. 2001. TRAF6 is a critical mediator of signal transduction by the viral oncogene latent membrane protein 1. EMBO J. 20:5678- 5691.
52. Schutyser, E., S. Struyf, and J. Van Damme. 2003. The CC chemokine CCL20 and its receptor CCR6. Cytokine Growth Factor Rev. 14:409-426.
53. Schwamborn, J., et al. 2003. Microarray analysis of tumor necrosis factor alpha induced gene expression in U373 human glioblastoma cells. BMC Genomics 4:46.
54. Shih, V. F., R. Tsui, A. Caldwell, and A. Hoffmann. 2011. A single NFκB system for both canonical and non-canonical signaling. Cell Res. 21:86-102.
55. Smale, S. T. 2010. Pioneer factors in embryonic stem cells and differentiation. Curr. Opin. Genet. Dev. 20:519-526.
56. Smoot, M. E., K. Ono, J. Ruscheinski, P. L. Wang, and T. Ideker. 2011. Cytoscape 2.8: new features for data integration and network visualization. Bioinformatics 27:431-432.
57. Smyth, G. K. 2004. Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat. Appl. Genet. Mol. Biol. 3:Article3.
58. Song, Y. J., K. M. Izumi, N. P. Shinners, B. E. Gewurz, and E. Kieff. 2008. IRF7 activation by Epstein-Barr virus latent membrane protein 1 requires localization at activation sites and TRAF6, but not TRAF2 or TRAF3. Proc. Natl. Acad. Sci. U. S. A. 105:18448-18453.
59. Tan, E. L., G. Selvaratnam, R. Kananathan, and C. K. Sam. 2006. Quantification of Epstein-Barr virus DNA load, interleukin-6, interleukin-10, transforming growth factor-β1 and stem cell factor in plasma of patients with nasopharyngeal carcinoma. BMC Cancer 6:227.
60. Thornburg, N. J., and N. Raab-Traub. 2007. Induction of epidermal growth factor receptor expression by Epstein-Barr virus latent membrane protein 1 C-terminal-activating region 1 is mediated by NF-κB p50homodimer/Bcl-3 complexes. J. Virol. 81:12954-12961.
61. Tian, B., D. E. Nowak, and A. R. Brasier. 2005. A TNF-induced gene expression program under oscillatory NF-κB control. BMC Genomics 6:137.
62. Valouev, A., et al. 2008. Genome-wide analysis of transcription factor binding sites based on ChIP-Seq data. Nat. Methods 5:829-834.
63. Viemann, D., et al. 2004. Transcriptional profiling of IKK2/NF-kappa B- and p38 MAP kinase-dependent gene expression in TNF-alpha-stimulated primary human endothelial cells. Blood 103:3365-3373.
64. Vockerodt, M., et al. 2008. The Epstein-Barr virus oncoprotein, latent membrane protein-1, reprograms germinal centre B cells towards a Hodgkin's Reed-Sternberg-like phenotype. J. Pathol. 216:83-92.
65. Wang, D., D. Liebowitz, and E. Kieff. 1985. An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell 43:831-840.
66. Wang, F., et al. 1990. Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23. J. Virol. 64: 2309-2318.
67. Wei, W. I., and J. S. Sham. 2005. Nasopharyngeal carcinoma. Lancet 365: 2041-2054.
68. Wu, L., H. Nakano, and Z. Wu. 2006. The C-terminal activating region 2 of the Epstein-Barr virus-encoded latent membrane protein 1 activates NF-κB through TRAF6 and TAK1. J. Biol. Chem. 281:2162-2169.
69. Zhao, B., S. A. Stavchansky, R. A. Bowden, and P. D. Bowman. 2003. Effect of interleukin-1β and tumor necrosis factor-α on gene expression in human endothelial cells. Am. J. Physiol. Cell Physiol. 284:C1577-C1583.